Banner - NPPA Connect
Logo Image
Quiz|Articles|August 24, 2026

Tudriqev: Test Your Clinical Knowledge

Listen
0:00 / 0:00

Key Takeaways

  • FDA accelerated approval established Tudriqev plus nivolumab for unresectable/metastatic cutaneous melanoma with progression on prior anti–PD-1 therapy.
  • Engineered oncolytic viral immunotherapy is differentiated by systemic response signals, suggesting activity beyond local, injected tumors.
SHOW MORE

Test your knowledge of Tudriqev’s accelerated approval, clinical activity, administration, and ongoing confirmatory research.

The FDA’s accelerated approval of Tudriqev (vusolimogene oderparepvec-wtpg; formerly RP1) in combination with nivolumab introduced another treatment option for adults with unresectable or metastatic cutaneous melanoma following progression on anti–PD-1 therapy. The approval comes amid a continued need for additional options for patients whose disease progresses after PD-1–based treatment.

In an interview with Dermatology Times, Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed what clinicians should know about the approval, including the systemic responses observed with the oncolytic therapy, multidisciplinary considerations for treatment delivery, and the clinical benefit being evaluated in the ongoing IGNYTE-3 confirmatory trial.

What was the basis for Tudriqev's accelerated approval in advanced cutaneous melanoma following anti-PD-1 therapy?


What does the abscopal effect described by Levy refer to in the context of Tudriqev treatment?


Which specialist may be needed when Tudriqev is injected into visceral lesions under imaging guidance?


Which clinical benefit end points does Levy say the IGNYTE-3 confirmatory trial is evaluating?


Which emerging therapeutic strategy did Levy discuss for anti–PD-1-refractory melanoma?


How Did You Score?

Tudriqev’s approval adds to an evolving treatment landscape for patients with advanced melanoma following anti–PD-1 therapy. As the confirmatory IGNYTE-3 trial continues, clinicians will be watching for longer-term evidence of clinical benefit, safety, and systemic responses.

Want to Learn More?

Explore the full interview with Joan Levy, PhD, for insights on Tudriqev’s accelerated approval, its role in PD-1-refractory melanoma, and what clinicians should watch next.

References

  1. FDA approves new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. FDA. Published November 25, 2025. Accessed August 21, 2026. FDA approval announcement
  2. Heaning S. What Tudriqev’s approval means for PD-1-refractory melanoma. Dermatology Times. August 2026. Dermatology Times interview

Related Content

Latest CME

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

View more
Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches
Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

View more
Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes
Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

View more